Interestingly, that the recombinant, dual-target MDM2/MDMX inhibitor could reverse doxorubicin resistance via the activation of the TAB1/TAK1/p38 MAPK cascade in breast cancer cells [41] is consistent with our result. This evidence concerns the gene MDM2 and breast cancer.